帕立骨化醇治疗维持性血液透析患者继发性甲状旁腺功能亢进的疗效

周 玮玮, 郭 杰, 王 祎熙

摘要


目的：观察帕立骨化醇治疗维持行血液透析患者继发性甲状旁腺功能亢进的疗效。方法：分析60例血液透析SHPT患者的临床资料，按照治疗的差异进行分组，分为治疗组（帕立骨化醇）30例，对照组（骨化三醇）30例，比较两组的治疗效果。结果：治疗组总有效率93.33%显著高于对照组73.33%的总有效率（P＜0.05）；治疗后12周患者碱性磷酸酶水平无显著差异（P＞0.05），治疗组血清钙水平较对照组上升不显著（P＜0.05），治疗组血清磷水平较对照组有所下降（P＜0.05）。结论：帕立骨化醇及骨化三醇都可降低iPTH，但帕立骨化醇在疗效上更显著，较小程度影响血清钙磷水平，且骨化三醇可造成钙的显著升高，进一步加重相关并发症，临床上治疗血液透析SHPT患者时可优先选用帕立骨化醇治疗。

关键词


继发性甲状旁腺功能亢进；血液透析；帕立骨化醇

全文:

PDF


参考


[1]Zhang L,Wang F,Wang L,et al.Prevalence of chronic kidney disease in China:a cross-sectional survey[J].Lancet,2012,379(9818):815-822.

[2]重磅！2020年度中国大陆血液透析统计数据报告，登记血透患者近70万人[OL].2021.http：//k.sina.com.cn/article_5828315414_15b65091601900xn10.html.

[3]王喆，姜埃利.帕立骨化醇对血液透析患者继发性甲状旁腺功能亢进疗效的Meta分析[J].中国血液净化，2014，13（3）：129-133.

[4]Liu Y, Liu LY, Jia Y, Wu MY, Sun YY, Ma FZ. Efficacy and safety of paricalcitol in patients undergoing hemodialysis: a meta-analysis. Drug Des Devel Ther. 2019 Mar 28;13:999-1009.

[5]Chen X, Zhao F, Pan WJ, Di JM, Xie WN, Yuan L, Liu Z. Paricalcitol in hemodialysis patients with secondary hyperparathyroidism and its potential benefits. World J Clin Cases. 2021 Nov 26;9(33):10172-10179. doi: 10.12998/wjcc.v9.i33.10172. PMID: 34904087; PMCID: PMC8638032.

[6]Stuart M. Sprague, Francisco Llach, Michael Amdahl,et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism[J].Kidney International, 2003, 63:1483-1490.

[7]Issa Al Salmi ,Brian Bieber,Mona Al Rukhaimi,et al.Parathyroid Hormone Serum Levels and Mortality among Hemodialysis Patients in the Gulf Cooperation Council Countries: Results from the DOPPS (2012-2018) [J].KIDNEY360,2020,1: 1083-1090.

[8]Jun Cheng, Wen Zhang, Xiaohui Zhang,et al.Efficacy and Safety of Paricalcitol Therapy for Chronic Kidney Disease: A Meta-Analysis[J].Clin J Am Soc Nephrol 2012,7: 391-400.

[9]Teresa Adragao,Johann Herberth,Marie-Claude Monier-Faugere,et al.Low Bone Volume—A Risk Factor for Coronary Calcifications in Hemodialysis Patients [J].Clin J Am Soc Nephrol 2009，4: 450-455.

[10]Ali ET, Mohammed AN, Khudairi AS, Sulaiman GM, Mohammed HA, Abomughayedh AM, Abomughaid MM. The Extensive Study of Magnesium Deficiency, 25-(OH) Vitamin D3, Inflammatory Markers, and Parathyroid Hormone in Relation to Bone Mineral Density in Iraqi Osteoporosis Patients: A Cross-Sectional Study. Health Sci Rep. 2025 Apr 9;8(4):e70641.

[11]周妍.两药联用治疗血液透析继发性甲状旁腺功能亢进的临床研究[J].当代医学，2019，25（15）：156-157.

[12]杨军，曾建.维持性血液透析患者血清钙磷及PTH水平与心脏结构功能的相关性[J].中国临床研究，2019，32（4）：527-530.

[13]Henry N, Hildebrand S, Cunningham J. Management of osteoporosis in chronic kidney disease. Clin Kidney J. 2025 Jul 16;18(10):sfaf228. doi: 10.1093/ckj/sfaf228. PMID: 41104260; PMCID: PMC12525161.


Refbacks

  • 当前没有refback。